Oncopeptides AB Interim Report April - June 2017
Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the second quarter 2017 report. ”It is gratifying that our pivotal Phase III study OCEAN commenced during the quarter, according to our strategic plan. This is a milestone for Ygalo® and for us as a company, and takes us one step closer to making Ygalo® available for late-stage multiple myeloma patients.” said Jakob Lindberg, CEO of Oncopeptides. SUMMARY OF Q2 April 1st – June 30th 2017 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 67.3 (loss: 23.5) MSEK · Loss per share,